Page 2 - Deborah Telman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DeSantis Says He Would Sue the Drug Company Gilead for Trying to Keep People Alive

DeSantis Says He Would Sue the Drug Company Gilead for Trying to Keep People Alive
counterpunch.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from counterpunch.org Daily Mail and Mail on Sunday newspapers.

United statesNew yorkDeborah telmanDylan mulvaneyDonald trumpNew york timesFlorida state board of administrationGovernor desantisBud lightFlorida state board

How a drugmaker profited by slow-walking a promising HIV therapy

New York Times: Company devised plan to delay new drug’s release to maximise profits.

Slovak republicUnited statesColumbia universityNew yorkChristopher mortenDavid swisherJohn milliganRebecca robbinsNorbert bischofbergerTodd andersonDeborah telmanJames krellensteinJulie cunninghamWorld health organisationNew york timesDrug administration

How a drugmaker profited by slow-walking a promising HIV therapy

Today, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment and prevention, according to IQVIA, an industry data provider. One widely used product, Descovy, has a sticker price of $26,000 annually. Generic versions of its predecessor, Truvada, whose patents have expired, now cost less than $400 a year.

Slovak republicUnited statesNorbert bischofbergerJames krellensteinDavid swisherJohn milliganJulie cunninghamChristopher mortenDeborah telmanColumbia universityGilead sciencesUs national institutes of healthDrug administrationWorld health organizationNyt news serviceCentral florida

How a Drug Maker Profited by Slow-Walking a Promising H I V Therapy

In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The public explanation was that it wasn’t sufficiently

Slovak republicUnited statesNew yorkColumbia universityJulie cunninghamDeborah telmanChristopher mortenJohn milliganJames krellensteinDavid swisherNorbert bischofbergerWorld health organizationNew york timesUs national institutes of healthGilead sciencesDrug administration

How Gilead Profited by Slow-Walking a Promising H I V Therapy

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.

Slovak republicUnited statesJames krellensteinSusanc beachyNorbert bischofbergerChristopher mortenJulie cunninghamDeborah telmanJohn milliganDavid swisherUs national institutes of healthWorld health organizationGilead sciencesDrug administrationColumbia universityCentral florida